FDA Grants Breakthrough Designation to Speed Up Pediatric Insomnia Drug
Research

FDA Grants Breakthrough Designation to Speed Up Pediatric Insomnia Drug

By Marcus Reid · · 2 min read

FDA Authorization for Daridorexant: A New View on Pediatric Insomnia Treatment

The designation addresses an unmet medical need in children and adolescents with sleep disorders. Phase 2 clinical data showed substantial drug efficacy. A single 50 mg dose increased total sleep time by 50 minutes overall. For patients with neurodevelopmental conditions, this improvement reached 64 minutes. The study also confirmed a favorable safety and tolerability profile in children. No adverse effects related to substance abuse or withdrawal symptoms were noted.

Mechanism of Action and Study Design

Daridorexant, developed by Idorsia, is a dual orexin receptor antagonist (DORA). It selectively reduces wakefulness drive. This differs from general brain activity inhibition. This targeted approach optimizes its pharmacokinetic profile. The drug is mostly eliminated by the next morning, preventing accumulation. The Phase 2 study was multicenter, randomized, double-blind, and placebo-controlled. It tested 10 mg, 25 mg, and 50 mg doses over two weeks. One hundred sixty-five children and adolescents participated. The primary endpoint showed a statistically significant, dose-dependent improvement in objective total sleep time from baseline.

Clinical Context and Future Plans

Insomnia affects 8% to 12% of children and adolescents. The clinical burden is greater in those with neurodevelopmental disorders, including autism spectrum disorder and ADHD. Idorsia is currently gathering input from global health authorities. This input concerns the Phase 3 pediatric clinical development protocol. The company expects to start this new phase in the latter half of next year.

Expert Commentary and Company Updates

Amer Joseph, MD, Chief Medical Officer and Global Clinical Development Lead at Idorsia, stated that this recognition highlights both the urgent medical need and daridorexant's promising clinical evidence. The FDA decision is strongly based on the dosing study data. Idorsia also reported Q1 2026 results. These included data on daridorexant in children and expanded clinical evidence. Furthermore, QUVIVIQ sales grew by 62% in the first half of 2026. This advancement strongly supports the medical community fighting pediatric insomnia, offering a faster route to safer, more effective treatment for young people.

Leave a comment

Every comment is read before it goes live. You will see it published once approved. You can send at most 2 comments per hour.